A Phase 3, randomised, double-blind study of adjuvant immunotherapy with Nivolumab versus placebo after complete resection of stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 76K).
- Brady, Benjamin (Primary Chief Investigator (PCI))
- Baker, Emma (Project Manager)
Project: Research